Bausch & Lomb option for Mimetogen dry eye drug terminated
This article was originally published in Scrip
Executive Summary
Bausch & Lomb, a division of Valeant Pharmaceuticals, apparently did not exercise its option to license the Mimetogen Pharmaceuticals dry eye drug candidate MIM-D3 following recently reported positive Phase III results.